Deutsche Bank’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-81,083
| Closed | -$299K | – | 5791 |
|
|
2017
Q4 | $299K | Sell |
81,083
-244,491
| -75% | -$1M | ﹤0.01% | 3838 |
|
|
2017
Q3 | $1.33M | Sell |
325,574
-7,754
| -2% | -$29.7K | ﹤0.01% | 2807 |
|
|
2017
Q2 | $1.24M | Buy |
333,328
+39,541
| +13% | +$157K | ﹤0.01% | 2876 |
|
|
2017
Q1 | $1.22M | Buy |
293,787
+79,100
| +37% | +$333K | ﹤0.01% | 2526 |
|
|
2016
Q4 | $925K | Buy |
214,687
+34,197
| +19% | +$221K | ﹤0.01% | 2755 |
|
|
2016
Q3 | $1.77M | Buy |
180,490
+16,585
| +10% | +$118K | ﹤0.01% | 2436 |
|
|
2016
Q2 | $925K | Buy |
163,905
+69,011
| +73% | +$469K | ﹤0.01% | 2950 |
|
|
2016
Q1 | $720K | Buy |
94,894
+18,309
| +24% | +$141K | ﹤0.01% | 3005 |
|
|
2015
Q4 | $1.02M | Sell |
76,585
-15,394
| -17% | -$265K | ﹤0.01% | 2862 |
|
|
2015
Q3 | $1.51M | Buy |
91,979
+3,181
| +4% | +$65.2K | ﹤0.01% | 2671 |
|
|
2015
Q2 | $1.99M | Buy |
88,798
+7,230
| +9% | +$114K | ﹤0.01% | 2459 |
|
|
2015
Q1 | $796K | Buy |
81,568
+52,721
| +183% | +$517K | ﹤0.01% | 3015 |
|
|
2014
Q4 | $328K | Buy |
28,847
+28,733
| +25,204% | +$312K | ﹤0.01% | 3988 |
|
|
2014
Q3 | $1K | Sell |
114
-51,305
| -100% | -$784K | ﹤0.01% | 5830 |
|
|
2014
Q2 | $998K | Sell |
51,419
-7,717
| -13% | -$136K | ﹤0.01% | 2945 |
|
|
2014
Q1 | $1.06M | Sell |
59,136
-24,564
| -29% | -$403K | ﹤0.01% | 2824 |
|
|
2013
Q4 | $883K | Sell |
83,700
-10,238
| -11% | -$114K | ﹤0.01% | 2739 |
|
|
2013
Q3 | $1.16M | Sell |
93,938
-40,836
| -30% | -$430K | ﹤0.01% | 2860 |
|
|
2013
Q2 | $1.27M | Buy |
+134,774
| New | +$1.73M | ﹤0.01% | 2528 |
|
Deutsche Bank's CASC Position: Q1 2018 in Review
Deutsche Bank sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 81,083 shares — an estimated $299K sold.
Deutsche Bank first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $1.99M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Deutsche Bank reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Deutsche Bank sold 81,083 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $299K.
- Deutsche Bank first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Deutsche Bank's Cascadian Therapeutics, Inc. position peaked at $1.99M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Deutsche Bank's 13F filing for Q1 2018, filed 15 May 2018.